The Metabolically Resistant Apelin-17 Analogue LIT01-196 Reduces Cardiac Dysfunction and Remodelling in Heart Failure After Myocardial Infarction
Open Access
- 12 December 2024
- journal article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (5) , 911-924
Abstract
No abstract availableKeywords
Funding Information
- Sorbonne Université
- Paris-Saclay University
- French Federation of Cardiology
- Centre National de la Recherche Scientifique
- National Institute of Health and Medical Research
- Fondation du Collège de France
- Collège de France
- Foundation for Medical Research (PBR201810007643)
This publication has 34 references indexed in Scilit:
- Optimizing Foundational Therapies in Patients With HFrEFJACC: Basic To Translational Science, 2022
- Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic HeartMolecular Therapy, 2018
- Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptidesJournal of Molecular Medicine, 2011
- Cardiac fibroblasts: At the heart of myocardial remodelingPharmacology & Therapeutics, 2009
- The apelin–APJ system in heart failureBiochemical Pharmacology, 2008
- Plasma Connective Tissue Growth Factor is a Novel Potential Biomarker of Cardiac Dysfunction in Patients with Chronic Heart FailureEuropean Journal of Heart Failure, 2008
- Plasma Concentrations of the Novel Peptide Apelin are Decreased in Patients with Chronic Heart FailureEuropean Journal of Heart Failure, 2006
- Emerging roles of apelin in biology and medicinePharmacology & Therapeutics, 2005
- Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ ReceptorBiochemical and Biophysical Research Communications, 1998
- A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11Gene, 1993